`Scharschmidt et al.
`
`(10) Patent No.:
`(45) Date of Patent:
`
`US 9,561,197 B2
`*Feb. 7, 2017
`
`USO09561 197B2
`
`(54)
`
`(75)
`
`(73)
`
`(*)
`
`(21)
`(22)
`(65)
`
`(60)
`
`(51)
`
`(52)
`
`(58)
`
`(56)
`
`Assignee:
`
`METHODS OF THERAPEUTC
`MONITORING OF PHENYLACETIC ACID
`PRODRUGS
`Inventors: Bruce Scharschmidt, San Francisco,
`CA (US); Masoud Mokhtarani, Walnut
`Creek, CA (US)
`Horizon Therapeutics, LLC, Lake
`Forest, IL (US)
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 649 days.
`This patent is Subject to a terminal dis
`claimer.
`Appl. No.: 13/610,580
`Filed:
`Sep. 11, 2012
`
`Notice:
`
`Prior Publication Data
`US 2013/0281530 A1
`Oct. 24, 2013
`
`Related U.S. Application Data
`Provisional application No. 61/636,256, filed on Apr.
`20, 2012.
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`
`Int. C.
`A6 IK3I/92
`A6 IK 3L/26
`A6 IK 3L/225
`GOIN 33/68
`U.S. C.
`CPC ........... A61K 31/192 (2013.01); A61K 3 1/216
`(2013.01); G0IN 33/6812 (2013.01)
`Field of Classification Search
`CPC ............................ A61K 31/192: A61K 3 1/216
`See application file for complete search history.
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`8, 1981 Brusilow
`4,284,647 A
`7, 1984 Brusilow
`4,457.942 A
`8, 1997 Samid
`5,654,333 A
`5,968,979 A 10, 1999 Brusilow
`6,060,510 A
`5, 2000 Brusilow
`6,083,984 A
`7/2000 Brusilow
`6,219,567 B1
`4/2001 Eggers
`8,094,521 B2
`1/2012 Levy
`8.404,215 B1
`3/2013 Scharschmidt et al.
`8,642,012 B2
`2/2014 Scharschmidt
`2003. O1952.55 A1 10, 2003 Summar
`2004/0229948 A1
`11/2004 Summar
`2005/0273359 A1 12/2005 Young
`2006, O1356.12 A1
`6, 2006 Ferrante
`2008/O1195.54 A1
`5, 2008 Jalan
`2010, 0008859 A1
`1/2010 Scharschmidt
`2010, OO16207 A1
`1/2010 Wurtman et al.
`2012/0022157 A1
`1/2012 Scharschmidt
`2012fO220661 A1
`8, 2012 Lee
`2013,0210914 A1
`8, 2013 Scharschmidt
`2014/O142186 A1
`5/2014 Scharschmidt et al.
`
`FOREIGN PATENT DOCUMENTS
`
`WO
`WO
`
`WO94,22494
`WO 2005/0536O7
`
`10, 1994
`6, 2005
`
`WO WO 2006/056794
`WO WO 2007/005633
`WO WO 2009/087474
`WO WO 2009/134460
`WO WO 2010/O25303
`WO WO 2012/O28620
`WO WO2013/048558
`WO WO2013, 158145
`
`6, 2006
`1, 2007
`T 2009
`11/2009
`3, 2010
`3, 2012
`4/2013
`10, 2013
`
`OTHER PUBLICATIONS
`
`Ambrose, A.M., (1933) “Further Studies on the Detoxification of
`Phyenylacetic Acid.” J Biol Chem 101:669-675.
`Batshaw M.L. et al. (Dec. 1980) “Treatment of Hyperammonemic
`Coma Caused by Inborn Errors of Urea Synthesis,” J Pediatr
`97(6):893-900.
`Batshaw M.L. et al. (Jun. 10, 1982) "Treatment of Inborn Errors of
`Urea Synthesis: Activation of Alternative Pathways of Waste Nitro
`gen Synthesis and Excretion.” N. Engl J Med 306(23): 1387-1392.
`Batshaw, M.L. (1984) “Hyperammonemia,” in Current Problems in
`Pediatrics, Lockhart, J.D. ed.: Year Book Medical Publishers, pp.
`2-69.
`Batshaw, M.L. et al. (Aug. 1981) “New Approaches to the Diag
`nosis and Treatment of Inborn Errors of Urea Synthesis.” Pediatrics
`68(2):290-297.
`Berry, G.T. et al., (2001) "Long-term Management of Patients with
`Urea Cycle Disorders.” J Pediatrics 138:S56-S61.
`Brahe, C., et al., (2005) “Phenylbutyrate Increases SMN Gene
`Expression in Spinal Muscular Atrophy Patients.” Eur.J Hum Genet
`13:256-259.
`Brunetti-Pierri, N., et al., (2011) “Phenylbutyrate Therapy for
`Maple Syrup Urine Disease.” Hum Mol Genet 20(4):631-640.
`Brusilow, S.W., et al. (Sep. 1, 1979) “New Pathways of Nitrogen
`Excretion in Inborn Errors of Urea Synthesis.” Lancet 2(8140):452
`454.
`Brusilow, S.W., et al. (Feb. 8, 1980) “Amino Acid Acylation: A
`Mechanism of Nitrogen Excretion in Inborn Errors of Urea Syn
`thesis, Science 207:659-661.
`Brusilow, S.W., et al. (Jun. 21, 1984) “Treatment of Episodic
`Hyperammonemia in Children With Inborn Errors of Urea Synthe
`sis.” N. Engl J Med 310(25):1630-1634.
`Brusilow, S.W., et al. (1991) Phenylacetylglutamine May Replace
`Urea as a Vehicle for Waste Nitrogen Excretion. Pediatric Res
`29(2): 147-150.
`Brusilow, S.W., et al. (1991) "Treatment of Urea Cycle Disorders.”
`Chapter 5 in Treatment of Genetic Diseases, Desnik, R.J. et al. eds,
`Churchill Livingstone, New York, New York, pp. 79-94.
`Brusilow, S.W., et al. (1993) “Restoration of Nitrogen Homeostasis
`in a Man with Ornithine Transcarbamylase Deficiency.” J Metabo
`lism 42:1336-1339.
`Brusilow, S.W., et al. (Jul. 25, 1994—Amendment Dated) "Proto
`cols for Management of Intercurrent Hyperammonemia in Patients
`with Urea Cycle Disorders.” FDA Application to Market a New
`Drug for Human Use or an Antibiotic Drug for Human Use, 14
`pageS.
`Brusilow, S.W., et al. (1995) “Urea Cycle Disorders: Clinical
`Paradigm of Hyperammonemic Encephalopathy.” Prog Liver Dis
`eases 12:293-309.
`Brusilow, S.W., et al. (1995) “Urea Cycle Enzymes.” Chapter 32 in
`The Metabolic and Molecular bases of Inherited Diseases, Scriver,
`C.R. et al. eds., McGraw-Hill, Inc. New York, New York, pp.
`1187-1232.
`
`(Continued)
`Primary Examiner — Jeffrey S Lundgren
`Assistant Examiner — Sara E Townsley
`(57)
`ABSTRACT
`The present disclosure provides methods for adjusting the
`dosage of PAA prodrugs (e.g., HPN-100. PBA) based on
`measurement of PAA and PAGN in plasma and calculating
`the PAA:PAGN ratio So as to determine whether PAA to
`PAGN conversion is saturated.
`2 Claims, 7 Drawing Sheets
`
`1 of 29
`
`LUPIN EX. 1001
`
`
`
`US 9,561,197 B2
`
`Page 2
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`Brusilow, S.W., et al. (1996) “Urea Cycle Disorders: Diagnosis,
`Pathophysiology, and Therapy,” Adv Pediatr 43:127-170.
`Calloway, D.H. et al. (1971) “Sweat and Miscellaneous Nitrogen
`Losses in Human Balance Studies,” JNutrition 101:775-786.
`Calloway, D.H. et al. (1971) “Variation in Endogenous Nitrogen
`Excretion and Dietary Nitrogen Utilization as Determinants of
`Human Protein Requirements,” J Nutrition 101:205-216.
`Camacho, L.H. et al. “Phase I Dose Escalation Clinical Trial of
`Phenyl butyrate Sodium Administered Twice Daily to Patients With
`Advanced Solid Tumors,” Invest. New Drugs 25:131-138 (2007,
`e-pub. Oct. 20, 2006).
`Chang, J. et al., (2001) “Treatment of Spinal Muscular Atrophy by
`Sodium Butyrate,” PNAS 98(17):9808-9813.
`Chung, Y.L., et al., (2000) “A Novel Approach for Nasopharyngeal
`Carcinoma Treatment Uese Phenylbutyrate as a Protein Kinase C
`Modulator: Implications for Radiosensitization and EBV—Targeted
`Therapy,” Clin Cancer Res 6:1452-1458.
`ClinicalTrials.Gov/Archive View of NCT00551200 on Dec. 11,
`2007
`“Dose-Escalation
`Safety
`Study
`of Glyceryl
`Tri
`(4-Phenylbutyrate)(GT4P)
`to Treat Urea Cycle Disorders”
`[accessed Oct. 5, 2009], 4 pages.
`Comte, B. et al., (2002) “Identification of Phenylbutyrylglutamine,
`a new Metabolite of Phenylbutyrate Metabolism in Humans,” J
`Mass Spectrometry, 37(6):581-590.
`Cudkowicz, ALS (2009) “Phase 2 Study of Sodium Phenylbutyrate
`in ALS,” Amyotrophic Lateral Sclerosis 10:99-106.
`Deferrari, G. et al. (1981) “Brain Metabolism of Amino Acids and
`Ammonia in Patients with Chronic Renal Insufliciency,” Kidney
`International 20:505-510.
`Diaz, G.A., et al., (2011) “Phase 3 Blinded, Randomized, Crossover
`Comparison of Sodium Phenylbutyrate (NaPBA) and Glycerol
`Phenylbutyrate (GPB): Ammonia (NH3) Control in Adults with
`Urea Cycle Disorders (UCDs),” Mol. Genet. Metab. 102:276.
`Diaz, G.A.. et al.. “Phase 3 Blinded. Randomized, Crossover
`Comparison of Sodium Phenylbutyrate (NaPBA) and Glycerol
`Phenylbutyrate (GPB): Ammonia (NH3) Control in Adults with
`Urea Cycle Disorders (UCDs),” Mol. Genet. Metab. 102:276,
`Society ofInherited Metabolic Disease (SMID) Abstract.
`Enns, G.M.,
`et al.,
`(2007) “Survival After Treatment with
`Phenylacetate and Benzoate for Urea-Cycle Disorders,” N. Eng J
`Med 356:2282-2292.
`FDA Label for Buphenyl, 6 pages.
`FDA. “Buphenyl® (Sodium Phenylbutyrate) Label” nine pages
`(Aug. 2003).
`(Aug. 2, 2005) “Improved Survival of Neonates
`Gargosky, S.
`Following Administration ofAmmonul® (Sodium Phenyl acetate &
`Sodium Benzoate) 10% I 10% Injection,” SSIEM Poster, six pages.
`Gargosky, S. et al. (Oct. 14, 2005) “Results of a Twenty-two Year
`Clinical Trial: Actue, Adjunctive Pharmacological Treatment of
`Hyperammonemic Episodes
`in Patients with Deficiencies
`in
`Enzymes of the Urea Cycle,” poster, Ucyclyd Pharma, Inc., one
`page.
`Gargosky, S. (2006) “High Ammonia Levels Are Associated With
`Increased Mortality and Coma,” Ucyclyd Pharma, Inc., one page.
`Ghabril, M., et al., (2012) “Glycerol Phenylbutyrate (GPB) Admin-
`istration in Patients with Cirrhosis and Episodic Hepatic Encepha-
`lopathy (HE),” accepted for presentation at Digestive Disease Week.
`Gropman, AL, et al., (2008) “1H MRS Allows Brain Phenotype
`Differentiation
`in
`Sisters with
`Late Onset Ornithine
`Transcarbamylase Deficiency (OTCD) and Discordant Clinical Pre-
`sentations,” Mol Genet Metab 94(1):52-60.
`Gropman, AL. et al. (2008) “1H MRS Identifies Symptomatic and
`Asymptomatic Subjects With Partial Ornithine Transcarbamylase
`Deficiency,” Mol Genet Metab 95(1-2):21-30 (Sep.-Oct. 2008,
`e-pub. Jul. 26, 2008).
`Gropman, A. (2010) “Brain Imaging in Urea Cycle Disorders,” Mol
`Genet Metab 100:S20-S30.
`
`(2008) “Pulsed-Dosing with Oral Sodium
`Hines, P., et al.,
`Phenylbutyrate Increases Hemoglobin F in a Patient with Sickle
`Cell Anemia,” Pediatr Blood Cancer 50:357-359.
`Hogarth, P, et al., (2007) “Sodium Phenylbutyrate in Huntington’s
`Disease: A Dose-Finding Study,” Mov Disord 22(13):1962-1964.
`Huang, H.H., et al.,
`(2012) “Cannabinoid Receptor 2 Agonist
`Ameliorates Mesenteric Angiogenesis and Portosystemic Collater-
`als in Cirrhotic Rats,” Hepatology 56:248-258.
`Hyperion Therapeutics (Oct. 23, 2007) “Hyperion Therapeutics
`Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of
`GT4P in Patients with Urea Cycle Disorders” Announcement,
`1
`page.
`Hyperion Therapeutics. “Hyperion Therapeutics Announces Results
`for Phase 11 Study in Urea Cycle Disorders,” located at <http://
`www.hyperiontx.com/press/release/prl238518388,> last visited on
`Apr. 27, 2011, three pages (Mar. 30, 2009).
`Hyperion Therapeutics. “Hyperion Therapeutics Announces Results
`of Phase I Study in Patients with Liver Cirrhosis” located at
`<http://www.hyperionb<.com/press/release/pr
`1243891161>,
`last
`visited on Apr. 27, 2011, three pages (Jun. 2, 2009).
`James, M.O. et al. (1972) “The Conjugation ofPhenylacetic Acid in
`Man, Sub-Human Primates and Some Other Non-Primates Spe-
`cies,” Proc R Soc London 182:25-35.
`John, B.A. et al. (Mar. 2009) “The Disposition ofHPN-100, a Novel
`Pharmaceutical Under Development for Potential Treatment of
`Hyperammonemia,
`in Cynomolgus Monkeys,” ACMG 2009
`ADME, poster, two pages.
`John, B.A. et al. (Mar. 2009) “The Disposition ofHPN-100, a Novel
`Pharmaceutical Under Development for Potential Treatment of
`Hyperammonemia, in Cynomologus Monkeys,” abstract presented
`at ACMG 2009, one page.
`Kasumov, T. et al.,
`(2004) “New Secondary Metabolites of
`Phenylbutyrate in Humans and Rats,” Drug Metabolism and Dis—
`position 32(1):10-19.
`Lee, B. et al. (2008) “Preliminary data on adult patients with urea
`cycle disorders (UCD) in an open-label, switch-over dose-escala-
`tion study comparing a new ammonia scavenger, glyceryl tri(4-
`phenylbutyrate) (HPN-100), to buphenyl (sodium phenylbutyrate
`(PBA)).” J Inherited Metabolic Disease 31(1):91.
`Lee, B. et al.
`(2009) “Dosing and Therapeutic Monitoring of
`Ammona Scavenging Drugs and Urinary Phenylacetylglutamine
`(PAGN) as a Biomarker: Lessons From a Phase 2 Comparison of a
`Novel Ammonia Scavenging Agent with Sodium Phenylbutyrate
`(NAPBA),” presented at ICIEM 2009, San Diego, CA, poster, one
`page.
`(2009) “Dosing and Therapeutic Monitoring of
`Lee, B. et al.
`Ammonia Scavenging Drugs and Urinary Phenylacetylglutamine
`(PAGN) as a Biomarker: Lessons From a Phase 2 Comparison of a
`Novel Ammonia Scavenging Agent With Sodium Phenylbutyrate
`(NaPBA),” abstract presented at ICIEM 2009, San Diego, CA, one
`page.
`Lee, B. et al. (2009) “Phase 2 Study of a Novel Ammonia Scav-
`enging Agent
`in Adults With Urea Cycle Disorders (UCDs),”
`abstract presented at ACMG 2009, one page.
`Lee, B. et al. (2009) “Phase 2 Study of a Novel Ammonia Scav-
`enging Agent
`in Adults with Urea Cycle Disorders (UCDs),”
`presented at ACMG 2009, seventeen pages.
`Lee, B., et al. (2010) “Phase 2 Comparison of a Novel Ammonia
`Scavenging Agent with Sodium Phenylbutyrate in Patients with
`Urea Cycle Disorders: Safety, Pharmacokinetics and Ammonia
`Control,” Mol Genet Metab 100:221-228.
`Lewis, H.B. (1914) “Studies in the Synthesis oinppuric Acid in the
`Animal Organism. II. The Synthesis and Rate of Elimination of
`Hippuric Acid After Benzoate Ingestion in Man,” J Biol Chem
`18:225-231.
`(1986) “Longitudinal Data Analysis Using
`Liang, K.Y., et al.,
`Generalized Linear Models,” Biometrika 73(1): 13-22.
`Lichter-Konecki, U., et al., “Ammonia Control in Children with
`Urea Cycle Disorders (UCDs); Phase 2 Comparison of Sodium
`Phenyl butyrate and Glycerol Phenylbutyrate,” Mol Genet Metab
`103:323-329 (2011).
`MacArthur, R. B.,
`phenylacetate
`and
`
`sodium
`“Pharmacokinetics of
`al.,
`et
`soium benzoate
`following
`intravenous
`
`20f29
`
`LUPIN EX. 1001
`
`2 of 29
`
`LUPIN EX. 1001
`
`
`
`US 9,561,197 B2
`Page 3
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`
`
`administrtion as both a bolus and continuous infusion to healthy
`adult volunteers.” Mol Genet Metab 81:(1):S67-S73 (2004).
`Maestri, N. E. et a1. “Plasma Glutamine Concentration: A Guide in
`the Management of Urea Cycle Disorders,” J Pediatr 121(2):259-
`261(Aug. 1992).
`Mansour, A. et a1. “Abdominal Operations in Patients with Cirrho-
`sis: Still a Major Surgical Challenge,” Surgery 122(4):730-735.
`(Abstract Only.) (Oct. 1997).
`McGuire, B. et al. (2008) “Pharmacokinetic (PK) Safety Study of
`Sodium Phenylacetate and Sodium Benzoate Administered to Sub-
`jects with Hepatic Impairmen ,” abstract of The 13th International
`Symposium, Abano (Padova), Italy, Apr. 28-May 1, 2008,
`two
`pages.
`VIcGuire, B. et al. (2008) Pharmacokinetic Safety Study of Sodium
`Phenylacetate and Sodium Benzoate Administered to Subjects With
`Hepatic Impairments, Liver International 28:743. (Abstract Only).
`VIcGuire, B. et a1.
`(2009) “Pharmacokinetic (PK) and Safety
`Analyses of a Novel Ammonia-Reducing Agent in Healthy Adults
`and Patients with Cirrhosis,” Hyperion Therapeutics, poster, one
`page.
`(2009) “Pharmacokinetic (PK) and Safety
`VIcGuire, B. et a1.
`Analyses of a Novel Ammonia-Reducing Agent in Healthy Adults
`and Patients with Cirrhosis,” abstract presented at DDW, two pages.
`VIcGuire, B. et al., (2010) “Pharmacology and Safety of Glycerol
`Phenylbutyrate in Healthy Adults and Adults with Cirrhosis,”
`Hepatology 51:2077-2085.
`VIcQuade PS. (1984) “Analysis and the Effects of Some Drugs on
`the Metabolism of Phenylethylamine and Phenylacetic Acid,”
`Neuropsychopharmaco Biol Psychiat 8:607-614.
`VIercuri, E., et al., (2004) “Pilot Trial of Phenylbutyrate in Spinal
`VIuscular Atrophy,” Neuromuscul Disord 14:130-135.
`VIokhtarani, M., et al., (2012) “Elevated Phenylacetic Acid (PAA)
`Levels Appear Linked to Neurological Adverse Events in Healthy
`Adults But Not in Urea Cycle Disorder (UCD) Patients,” Mol Genet
`Metab 105:342.
`VIoldave, K., et al., (1957) “Synthesis of Phenylacetylglutamine by
`Human Tissue,” JBiol Chem 229:463-476.
`VIonteleone, JPR, et al., (2012) “Population pk Analysis of Glycerol
`Phenylbutyrate (GPB) and Sodium Phenylbutyrate(NAPBA) in
`Adult and Pediatric Patients with Urea Cycle Discorders,” Mol
`Genet Metab 105:343.
`Ong, J. P., et al., (2003) “Correlation Between Ammonia Levels and
`the Severity of Hepatic Encephalopathy,” Am J Med 114:188-193.
`Perrine, S. P., (2008) “Fetal Globin Stimulant Therapies in the
`Beta-Hemoglobinopathies: Principles
`and Current Potential,”
`Pediatr Ann 37(5):339-346.
`Piscitelli, SC. et al. (1995) “Disposition of Phenylbutyrate and its
`Metabolites, Phenylacetete and Phenylacetylglutamine,” J Clin
`Pharmacal 35:368-373.
`Propst, A. et a1. (1995) “Prognosis and Life Expectancy in Chronic
`Liver Disease,” Dig Dis Sci 40(8):1805-1815. (Abstract Only).
`Riley, T.R. et a1. (2001) “Preventive Strategies in Chronic Liver
`Disease: Part II. Cirrhoses,” Am Fam Physician 64(10):1735-1740.
`(Abstract Only).
`(1973) “Maximal Rates of Excretion and
`Rudman, D., et al.,
`Synthesis of Urea in Normal and Cirrhotic Subjects,” J Clin Invest
`52:2241-2249.
`Ryu, H., et al., (2005) “Sodium Phenylbutyrate Prolongs Survival
`and Regulates Expression of Anti-Apoptotic Genes in Transgenic
`Amyotrophic Lateral Sclerosis Mice,” JNeurochem 93:1087-1098.
`Shiple, G.J. et a1. (1922) “Synthesis of Amino Acids in Animal
`Organisms. I. Synthesis of Glycocoll and Glutamine in the Human
`Organism,” JAm Chem Soc 44:618-624.
`Simell, 0., et a1. (1986) “Waste nitrogen excretion via amino acid
`acylation: Benzoate and phyylacetate in lysinuric protein intoler-
`ance.” Ped Res 20(11):1117-1121.
`Singh, (2001) “Consensus Statement from a Conference for the
`Management of Patients with Urea Cycle Disorders,” Suppl to J
`Pediatrics 138(1):Sl-SS.
`
`(1998) “Oral L-ornithine-L-aspartate therapy of
`Stauch, et al.,
`chronic hepatic encephalopathy: results of a placebo-controlled
`double-blind study” J Hepatology 28(5):856-864.
`Summar, M. et al. (2007) “Description and Outcomes of 316 Urea
`Cycle Patients From a 21-Year, Multicenter Study of Acute
`Hyperammonemic Episodes,” Abstract, presented at Annual Sym-
`posium CCH%0ngress Centre Hamburg, Sep. 4-7, 2007,
`GSSIEM 2007, two pages.
`Summar, ML. et a1. “Diagnosis, Symptoms, Frequency and Mor-
`tality of 260 Patients with Urea Cycle Disorders From a 21-Year,
`Multicentre Study of Acute Hyperammonaemic Episodes,” Acta
`Paediatr 97:1420-1425 (Oct. 2008, e-pub. Jul. 17, 2008).
`Swedish Orphan International, “Urea Cycle Disorders an Interna-
`tional Perspective,” Poster, Symposium Swedish Orphan Interna-
`tional, Barcelona, Spain, Jan. 12, 2007, one page.
`Tanner, L. M., et al., (2007) “Nutrient intake in lysinuric protein
`intolerance.” J Inherited Metabolic Disease 30(5):716-721.
`Thibault, A. et al., (1994) “A Phase I and Pharmacokinetic Study of
`Intravenous Phenylacetate in Patients with Cancer,” Cancer Res
`54(7):1690-1694.
`Thibault, A., et al., (1995) “Phase I Study of Phenylacetate Admin-
`istered Twice Daily to Patients with Cancer,” Cancer 75(12):2932-
`2938.
`Tuchman, M. et a1. (2008) “Cross-Sectional Multicenter Study of
`Patients With Urea Cycle Disorders in the United States,” Malec
`Genetics Metab 94:397-402 (e-pub. Jun. 17, 2008).
`Waterlow, J.C. (1963) “The Partition of Nitrogen in the Urine of
`Malnourished Jamaican Infants,” Am J Clin Nutrition 12:235-240.
`Xie, G., et al., (2012) “Role of Diiferentiation of Liver Sinusoidal
`Endothelial Cells in Progression and Regression of Hepatic Fibrosis
`in Rats,” Gastroenterology 142:S918.
`Zeitlin, PL. et a1. (2002) “Evidence of CFTR Function in Cystic
`Fibrosis After System Administration of 4-Phenylbutyrate,” Mol
`Therapy 6(1):119-126.
`Combined Search and Examination Report for British Patent Appli-
`cation No. GB0915545.8, search completed Oct. 8, 2009, report
`dated Oct. 9, 2009.
`Combined Search and Examination Report for British Patent Appli-
`cation No. GB1013468.2, search completed Sep. 8, 2010, report
`dated Sep. 9, 2010.
`European Patent Oflice, Extended European Search Report for
`EP09739263 completed Nov. 2, 2011.
`European Patent Oflice, International Search Report and Written
`Opinion for PCT/US2009/055256 completed Dec. 18, 2009 and
`mailed Dec. 30, 2009.
`for British
`Examination Report
`GB0915545.8 dated Feb. 5, 2010.
`Examination Report
`for British
`GB0915545.8 dated May 11,2010.
`Examination Report
`for British
`GB0915545.8 dated Oct. 27, 2010.
`Examination Report
`for British
`GB1013468.2 dated Oct. 28, 2011.
`International Preliminary Report on Patentability (Ch I) for PCT/
`US2012/028620, completed Jun. 4, 2012 and mailed on Apr. 10,
`2014.
`International Preliminary Report on Patentability (Ch II) for PCT/
`US2012/028620, completed Aug. 22, 2013 and mailed Sep. 4, 2013.
`International Preliminary Report on Patentability for PCT/US2009/
`030362, completed Feb. 24, 2009 and mailed on Mar. 10, 2011.
`International Preliminary Report on Patentability for PCT/US2009/
`055256, completed on Aug. 27, 2009, mailed on Mar. 10, 2011.
`United States Patent and Trademark Oflice, International Search
`Report and Written Opinion for PCT/US2009/030362 mailed Mar.
`2, 2009.
`United States Patent and Trademark Oflice, International Search
`Report and Written Opinion for PCT/US2012/028620 mailed Jun.
`20, 2012.
`United States Patent and Trademark Oflice, International Search
`Report and Written Opinion for PCT/US2012/54673 mailed Nov.
`20, 2012.
`
`Patent Application No.
`
`Patent Application No.
`
`Patent Application No.
`
`Patent Application No.
`
`3of29
`
`LUPIN EX. 1001
`
`3 of 29
`
`LUPIN EX. 1001
`
`
`
`US 9,561,197 B2
`
`Page 4
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`United States Patent and Trademark Oflice, International Search
`Report and Written Opinion for PCT/US2013/71333 mailed Mar.
`28, 2014.
`Amodio, P., et al., “Detection of Minimal Hepatic Encephalopathy:
`Normalization and Optimization of the Psychometric Hepatic
`Encephalopathy Score. A Neuropsychological and Quantified EEG
`Study,” J. Hepatol. 49:346-353 (2008).
`ANDA Notice Letter, Par Pharmaceutical, Inc. to Hyperion Thera-
`peutics, inc.. Re: Glycerol Phenylbutyrate 1.1 gm/ml oral liquid;
`US. Pat. Nos. 8,404,215 and 8,642,012 Notice of Paragraph IV
`Certification Mar. 12, 2014.
`Bajaj, J. S., et al., “Review Article: The Design of Clinical Trials in
`Hepatic EncephalopathyiAn International Society for Hepatic
`Encephalopathy and Nitrogen Metabolism (ISHEN) Consensus
`Statement,” Aliment Pharmacol Ther. 33 (7):739-747 (2011).
`Barsotti, Measurement of Ammonia in Blood, 138 J. Pediatrics,
`811-820 (2001).
`Batshaw, et al., Treatment of Carbamyl Phosphate Synthetase
`
`Deficiency with Keto Analogues of Essential Amino Acids, 292 The
`
`
`
`New England J. Medicine, 1085 90 (1975).
`Batshaw, M. L. et. al., Alternative Pathway Therapy for Urea Cycle
`Disorder: Twenty Years Later, 138 J. Pediatrics S46 (2001).
`Blau, Duran, Blaskovics, Gibson (editors), Physician’s Guide to the
`Laboratory Diagnosis of Metabolic Diseases, 261-276 (2d ed.
`1996).
`Blei, A. T., et al., “Hepatic Encephalopathy,” Am. J. Gastroenterol.
`96(7):1968-1976 (2001 ).
`Burlina, A.B.
`et
`al., Long-Term Treatment with Sodium
`Phenylbutyrate in Ornithine Transcarbamylase-Deficient Patients,
`72 Molecular Genetics and Metabolism 351-355 (2001).
`Carducci, M., Phenylbutyrate Induces Apopto sis in Human Prostate
`Cancer and Is More Potent Than Phenylacetate, 2 Clinical Cancer
`Research 379 (1996).
`Carducci, M.A. et al., A Phase I Clinical and Pharmacological
`Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Sched-
`ule, 7 Clin. Cancer Res. 3047 (2001).
`Center for Drug Evaluation and Research, Clinical Pharmacology
`and Biopharmaceutics Review for New Drug Application No.
`20-645 (Ammonu1®) (2005).
`Center for Drug Evaluation and Research, Labeling for New Drug
`Application No. 20-645 (Ammonul®) (2005).
`Center for Drug Evaluation and Research, Medical Review for New
`Drug Application No. 20-645 (Ammonul®) (2005).
`Chen, Z. et al., Tributyrin: A Prodrug of Butyric Acid for Potential
`Clinical Application in Differentiation Therapy, 54 Cancer Research
`3494 (1994).
`Clay, A. et. al, Hyperammonemia in the ICU, 132 Chest 1368
`(2007).
`Collins, A.F. et al., Oral Sodium Phenylbutyrate Therapy in
`Homozygous Beta Thalassemia: A Clinical Trial, 85 Blood 43
`(1995).
`Conn, H. 0., et al., “Liver Physiology and Disease: Comparison of
`Lactulose and Neomycin in the Treatment of Chronic Portal-
`Systemic Encephalopathy. A Double Blind Controlled Trial,” Gas-
`troenterology 72(4):573-583 (1977).
`Cordoba, J., “New Assessment of Hepatic Encephalopathy,” Journal
`of Hepatology 54: 1030-1040 (2011 ).
`Darmaun, D. et al., Phenylbutyrate-Induced Glutamine Depletion in
`Humans: Effect on Leucine Metabolism, 5 Am. J. of Physiology:
`Endocrinology and Metabolism E801 (1998).
`Diaz, G. A., et al., “Ammonia Control and Neurocognitive Outcome
`Among Urea Cycle Disorder Patients Treated with Glycerol
`Phenylbutyrate,” Hepatology 57(6):2171-2179 (2013).
`Dixon, M. A. and Leonard, J.V., Intercurrent Illness in Inborn Errors
`of Intermediary Metabolism, 67 Archives of Disease in Childhood
`1387 (1992).
`Dover, G. et al, Induction of Fetal Hemoglobin Production in
`Subjects with Sickle Cell Anemia by Oral Sodium Phenylbutyrate,
`54 Cancer Research 3494 (1994).
`
`Endo, F. et al., Clinical Manifestations of Inborn Errors of the Urea
`Cycle and Related Metabolic Disorders During Childhood, 134 J.
`Nutrition 16058 (2004).
`European Medicines Agency, Annex I: Summary of Product Char-
`acteristics for Ammonaps.
`European Medicines Agency, European Public Assessment Report:
`Summary for the Public for Ammonaps (2009).
`European Medicines Agency, Scientific Discussion for Ammonaps
`(2005).
`European Medicines Agency, Scientific Discussion for Carbaglu
`(2004).
`FDA Label for Carbaglu, seven pages. (Mar. 2010).
`Feillet, F. and Leonard, J.V., Alternative Pathway Therapy for Urea
`Cycle Disorders, 21 J. Inher. Metab. Dis. 101-111 (1998).
`Feoli-Fonseca, M. L., Sodium Benzoate Therapy in Children with
`Inborn Errors of Urea Synthesis: Effect on Carnitine Metabolism
`and Ammonia Nitrogen Removal, 57 Biochemical and Molecular
`Medicine 31 (1996).
`Ferenci, P, et al., “Hepatic EncephalopathyiDefinition, Nomen-
`clature, Diagnosis, and Quantification: Final Report of the Working
`Party at the 11th World Congresses of Gastroenterology, Vienna,
`1998,” Hepatology 35:716-721 (2002).
`Fernandes, Saudubray, Berghe (editors), Inborn Metabolic Diseases
`Diagnosis and Treatment, 219-222 (3d ed. 2000).
`Geraghty, MT and Brusilow, S.W., Disorders of the Urea Cycle, in
`Liver Disease in Children 827 (F.J. Suchy et al., eds. 2001).
`Ghabril, M. et al., “Glycerol Phenylbutyrate in Patients with Cir-
`rhosis and Episodic Hepatic Encephalopathy: A Pilot Study of
`Safety and Effect on Venous Ammonia Concentration,” Clinical
`Pharmacology in Drug Development 2(3): 278-284 (2013).
`Gilbert, J. et al., A Phase I Dose Escalation and Bioavailability
`Study of Oral Sodium Phenylbutyrate in Patients with Refractory
`Solid Tumor Malignancies, 7 Clin. Cancer Research 2292-2300
`(2001).
`Gore, S. et al., Impact of the Putative Differentiating Agent Sodium
`Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid
`Leukemia, 7 Clin. Cancer Res. 2330 (2001).
`Gropman, AL et al., Neurological Implications of Urea Cycle
`Disorders, 30 J. Inherit Metab Dis. 865 (2007).
`Hassanein, T.
`I.,
`et
`al., “Randomized Controlled Study of
`Extracorporeal Albumin Dialysis for Hepatic Encephalopathy in
`Advanced Cirrhosis,” Hepatology 46:1853-1862 (2007).
`Hassanein, T. I., et al., “Introduction to the Hepatic Encephalopathy
`Scoring Algorithm (HESA),” Dig. Dis. Sci. 53:529-538 (2008).
`Hassanein, T., et al., “Performance of the Hepatic Encephalopathy
`Scoring Algorithm in a Clinical Trial of Patients With Cirrhosis and
`Severe Hepatic Encephalopathy,” Am. J. Gastroenterol. 104:1392-
`1400 (2009).
`Honda, S. et al., Successful Treatment of Severe Hyperammonemia
`Using Sodium Phenylacetate Power Prepared in Hospital Pharmacy,
`25 Biol. Pharm. Bull. 1244 (2002).
`International Search Report and Written Opinion for PCT/USO9/
`30362, mailed Mar. 2, 2009, 8 pages.
`International Search Report and Written Opinion for PCT/US2009/
`055256, mailed Dec. 30, 2009, 13 pages.
`Inter Partes Review of US. Pat. No. 8,404,215 Petition Apr. 29,
`2015.
`Inter Partes Review of US. Pat. No. 8,642,012 Petition Apr. 29,
`2015.
`Kleppe, S. et al., Urea Cycle Disorders, 5 Current Treatment
`Options in Neurology 309-319 (2003).
`Kubota, K. and Ishizaki, T., Dose-Dependent Pharmacokinetics of
`Benzoic Acid Following Oral Administration of Sodium Benzoate
`to Humans, 41 Eur. J. Clin. Pharmacol. 363 (1991).
`Lee, B. and Goss, J., Long-Term Correction of Urea Cycle Disor-
`ders, 138 J. Pediatrics S62 (2001).
`Lee, B. et al., Considerations in the Diflicult-to-Manage Urea Cycle
`Disorder Patient, 21 Crit. Care Clin. $19 (2005).
`Lee, B., et al., “Optimizing Ammonia (NH3) Control in Urea Cycle
`Disorder (UCD) Patients: A Predictive Model,” Oral Abstract Plat-
`form Presentations, Biochemical Genetics, Phoenix, AZ, Mar. 22,
`2013.
`
`4of29
`
`LUPIN EX. 1001
`
`4 of 29
`
`LUPIN EX. 1001
`
`
`
`US 9,561,197 B2
`Page 5
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`
`Leonard, J.V. Urea Cycle Disorders, 7 Semin. Nenatol. 27 (2002).
`Lizardi-Cervera, J. et al., Hepatic Encephalopathy: A Review, 2
`Annals of Hepatology 122-120 (2003).
`MaestriNE, et al., Prospective treatment of urea cycle disorders. J
`Paediatr 1991; 119:923-928.
`Maestri, N.E., et al., Long-Term Survival of Patients with
`Argininosuccinate Synthetase Deficiency, 127 J. Pediatrics 929
`(1995).
`Maestri, N.E., Long-Term Treatment of Girls with Ornithine
`Transcarbamylase Deficiency, 355 N. Engl. J. Med. 855 (1996).
`Majeed, K., Hyperammonemia, eMedicine.com (Dec. 2001).
`Marini, J.C. et al., Phenylbutyrate Improves Nitrogen Disposal via
`an Alternative Pathway without Eliciting an Increase in Protein
`Breakdown and Catabolism in Control and Ornithine
`Transcarbamylase-Deficient Patients, 93 Am. J. Clin. Nutr. 1248
`(2011).
`Matsuda, I., Hyperammonemia in Pediatric Clinics: A Review of
`Ornithine Transcarbamylase Deficiency (OTCD) Based on our Case
`Studies, 47 JMAJ 160 (2004).
`Mizutani, N. et al., Hyperargininemia: Clinical Course and Treat
`ment with Sodium Benzoate and Phenylacetic Acid, 5 Brain and
`Development 555 (1983).
`Mokhtarani, M., et al., (2013) “Elevated Phenylacetic Acid Levels
`Do Not Correlate with Adverse Events in Patients with Urea Cycle
`Disorders o rHepatic Encephalopathy and Can Be Predicted Based
`on the Plasma PAA to PAGN Ratio.” Mol Genet Metab 110(4):446
`453.
`Mokhtarani, M., et al., (2012) “Urinary Phenylacetylglutamine as
`Dosing Biomarker for Patients with Urea Cycle Disorders,” Mol
`Genet Metab 107(3):308-314.
`Monteleone, JPR, et al., (2013) “Population Pharmacokinetic Mod
`eling and Dosing Simulations of Nitrogen-Scavenging Compounds:
`Disposition of Glycerol Phenylbutyrate and Sodium Phenylbutyrate
`in Adult and Pediatric Patients with Urea Cycle Disorders,” J. Clin.
`Pharmacol. 53(7): 699-710.
`Munoz, S. J., “Hepatic Encephalopathy,” Med. Clin. N. Am.
`92:795-812 (2008).
`Nassogne, M.C., Urea Cycle Defects: Management and Outcome,
`28 J. Inherit. Metab. Dis. 407 (2005).
`New England Consortium of Metabolic Programs, Acute Illness
`Protocol: Urea Cycle Disorders: The Infant/Child with Argininosuc
`cinate Lyase Deficiency, adapted from Summar, M and Tuchman,
`M. Proceedings of a Consensus Conference for the Management of
`Patients with Urea Cycle Disorders, 138 J. Peds. Suppl. S6 (2001).
`New England Consortium of Metabolic Programs, Acute Illness
`Protocol: Urea Cycle Disorders: The Infant/Child with Citrul
`linemia, adapted from Summar, M and Tuchman, M. Proceedings of
`a Consensus Conference for the Management of Patients with Urea
`Cycle Disorders, 138 J. Peds. Suppl. S6 (2001).
`Newmark. H. L. and Young, W. C. Butyrate and Phenylacetate as
`Differentiating Agents: Practical Problems and Opportunities, 22 J.
`Cellular Biochemistry 247 (1995).
`Ortiz, M., et al., “Development of a Clinical Hepatic Encephalopa
`thy Staging Scale.” Aliment Pharmacol Ther 26:859-867 (2007).
`Par Pharmaceutical, Inc.'S Initial Invalidity Contentions and Non
`Infringement Contentions for U.S. Pat. Nos. 8,404.215 and
`8,642,012.
`Parsons-Smith, B. G., et al., “The Electroencephalograph in Liver
`Disease.” Lancet 273:867-871 (1957).
`Phuphanich, S. et al., Oral Sodium Phenylbutyrate in Patients with
`Recurrent Malignant Gliomas: A Dose Escalation and
`Pharmacologic Study, Neuro-Oncology 177 (2005).
`Praphanpro. V. et al. Three Cases of Intravenous Sodium Benzoate
`and Sodium Phenylacetate Toxicity Occurring in the Treatment of
`Acute Hyperammonemia, 23 J. Inherited Metabolic Disease 129
`(2000).
`Rockey, D.C., et al., “Randomized, Controlled, Double Blind Study
`of Glycerol Phenylbutyrate in Patients with Cirrhosis and Episodic
`Hepatic Encephalopathy.” Hepatology 56:248(A) (2012).
`
`Salam, M., et al., “Modified-Orientation Log to Assess Hepatic
`Encephalopathy.” Aliment Pharmacol Ther. 35.(8):913-920 (2012).
`Scientific Discussion for Ammonaps, EMEA 2005, available at
`http://www.ema.europa.eu/docs/en GB/document library/
`EPAR Scientific Discussion/human/000219/WC500024748.
`pdf.
`Scottish Medicines Consortium, Carglumic Acid 200 mg Dispers
`ible Tablets (CarbaglucR) No. 299/06 (Sep. 8, 2006).
`Urinary
`Seakins,
`J.W.T.,
`The
`Determination
`of
`Phenylacetylglutamine as Phenylacetic Acid: Studies on its Origin
`in Normal Subjects and Children with Cystic Fibrosis, 35 Clin.
`Chim. Acta. 121 (1971).
`Sherwin, C. et al., The Maximum Production of Glutamine by the
`Human Body as Measured by the Output of Phenylacetylglutamine,
`37 J. Biol. Chem. 11